comscoreMetastatic Breast Cancer

Metastatic Breast Cancer

33 Research news
 
 
Article
Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care

Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

 
Article
Adding Aromatase Inhibitor to Perjeta and Herceptin Offers Benefits for Advanced-Stage Disease in Early Study

The combination of Perjeta, Herceptin, and an aromatase inhibitor led to longer progression-free survival than only Herceptin and an aromatase inhibitor in women diagnosed with advanced-stage HER2-positive, hormone-receptor-positive disease.

 
Article
Nexavar May Make Metastatic Cancers Start Responding to Hormonal Therapy Again

A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.

 
Article
Xgeva Slightly Better Than Zometa at Reducing Breast Cancer Bone Complications

Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones.

 
Article
Tykerb and Xeloda Can Help Treat Breast Cancer That's Spread to the Brain

A small, early study found that treating women diagnosed with metastatic, HER2-positive breast cancer that has spread to the brain with a combination of Tykerb and Xeloda can shrink the cancer in some women.

 
Article
Xgeva More Likely to Cause Osteonecrosis of the Jaw in Women Diagnosed With Advanced-Stage Breast Cancer

Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.

 
Article
Experimental Abemaciclib Improves Survival in Metastatic, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Experimental abemaciclib in combination with Faslodex offered better progression-free survival than Faslodex alone in women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer.

 
Article
Faslodex and Arimidex Better Than Arimidex Alone as First Treatment for Hormone-Receptor-Positive Metastatic Breast Cancer

Adding Faslodex to Arimidex as the first treatment for metastatic hormone-receptor-positive breast cancer improved overall survival by nearly 8 months compared to Arimidex alone, according to a study.

 
Article
Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.

 
Article
Adding Tukysa to Standard Treatment Reduces Brain Lesion Growth Risk in HER2-Positive Metastatic Breast Cancer

For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.

 
Article
Combo of Tykerb, Herceptin, and Aromatase Inhibitor Seems Best for Metastatic, HER2-Positive, Hormone-Receptor-Positive Disease

The combination of Tykerb, Herceptin, and an aromatase inhibitor seems better than just Herceptin and an aromatase inhibitor or just Tykerb and an aromatase inhibitor for treating metastatic HER2-positive, hormone-receptor-positive breast cancer in postmenopausal women.

 
Article
ASCO Issues Guidelines on Using Biomarkers to Make Treatment Decisions in Women Diagnosed With Metastatic Disease

The American Society of Clinical Oncology has issued new recommendations on using biomarkers to make metastatic breast cancer treatment decisions.

 
Article
Supervised Exercise Safe for People With Bone Metastases

People diagnosed with metastatic cancer that has spread to the bones can safely participate in supervised exercise programs, according to a review of 17 studies.

 
Article
Xgeva Better Than Zometa at Reducing Risk of Bone Problems in Women With Metastatic Disease

Research suggests that Xgeva is better than Zometa at reducing the risk of bone complication and improves quality of life more in women diagnosed with metastatic breast cancer that has spread to the bones.

 
Article
Breast Cancer's Hormone Receptor and HER2 Status Can Change After Diagnosis

The characteristics of a breast cancer -- including hormone receptor status and HER2 status -- can change over time. These changes may happen because the cancer cells change themselves or because treat...

 
Article
Higher Faslodex Dose Better for Recurrent or Metastatic Breast Cancer

A study has found that women diagnosed with recurrent or metastatic, hormone-receptor-positive breast cancer lived longer when they got 500 mg of Faslodex compared to women who got 250 mg of Faslodex.

 
Article
Faslodex Offers Better Survival Than Arimidex as First Treatment for Women With Advanced-Stage Disease

A study has found that using Faslodex as the first treatment for hormone-receptor-positive, advanced-stage breast cancer offers better survival than using Arimidex as the first treatment.

 
Article
Study Suggests Earlier Research on CYP2D6 Is Flawed

A study by researchers at the Mayo Clinic suggests that the large studies on the link between CYP2D6 and tamoxifen's effectiveness may be flawed because the studies did the genetic testing on samples of tissue from the breast cancer rather than on healthy tissue.

 
Article
Palbociclib (Also Called Ibrance) Approved by FDA

The FDA has granted accelerated approval for using the targeted therapy Ibrance in combination with Femara to treat advanced-stage, estrogen-receptor-positive, HER2-negative breast cancer that hadn't been treated with hormonal therapy before in postmenopausal women.

 
Article
Ibrance Offers Benefits as Second-Line Treatment for Advanced-Stage Disease

A study has found that Ibrance combined with Faslodex more than doubled progression-free survival compared to Faslodex alone in postmenopausal women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage breast cancer that had grown while being treated with hormonal therapy.

 
Article
FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer

On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.

 
Article
Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.

 
Article
FDA Approves Tukysa for Advanced-Stage HER2-Positive Breast Cancer

On April 17, 2020, the FDA approved Tukysa in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer, or locally advanced HER2-positive disease that can't be completely removed with surgery, after the cancer had been treated with at least one anti-HER2 medicine.

 
Article
Adding Tukysa to Standard of Care Continues To Improve Survival in Advanced-Stage HER2-Positive Breast Cancer

Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

Showing 24 of 33